Everyone is entitled to their own opinions, including people...

Everyone is entitled to their own opinions, including people with a contrarian view on a stock. You buy and sell when you believe is the right time. Unfortunately there are people who play the man and not the ball.

Today's announcement was a bit of a surprise. Rebecca said back on the 5th Feb that there would be updates coming out shortly about this trial. Then she said that they would hold on to the results until the ASH conference.

Interesting thing is, when you read the Quarterly, they had only dosed one patient by the 31st March (as per Quarterly). So I don't know what news she was talking about back at the start of Feb. And it seems they've had a change of heart and decided to release some results. Well done to the Company for doing that. What we need to keep in mind is there have been three patients dosed since the Frontline trial was announced in December 2024. Thee patients in six months. So they need to dose 17 more in the remaining six months.

What we need to see released - and results that the Company would be in possession of - in order to maintain the positive trend is this:

1. Updates on the one patient who had reported a complete response in the trial at Case Western (reported 07/10/24) Where are the 60 and 90 day results?
2. The further three patients dosed in this trial (As per Quarterly)
3. CHM CDH-17 updates on Patient 2 and Patient 3 - 60 and 90 day results

The CDH-17 trial is running way behind schedule. They have only dosed one patient this year! According to the Company's announcements, they should be dosing one patient every 28 days and have dosed 15 patients by the end of July this year.

Maybe they should focus on the CORE-NK trials where CHM only contribute 10% of the cost and put CDH-17 on the back-burner as that costs $750,000 per patient.